Brief: Ultimovacs Announces Results Of UV1-103 Phase I Trial

Zelluna ASA

28/06/2023 15:41

June 28 (Reuters) - Ultimovacs ASA  ULTI.OL :
    * RESULTS FROM UV1-103 TRIAL PUBLISHED IN CLINICAL CANCER
RESEARCH
HIGHLIGHT PROMISING EFFICACY AND SAFETY OF UV1 AND PEMBROLIZUMAB
IN MALIGNANT MELANOMA
    * BIOMARKER ANALYSES DEMONSTRATE STRONG CLINICAL EFFICACY
ALSO IN
PATIENTS CONSIDERED LESS LIKELY TO RESPOND TO MONOTHERAPY
CHECKPOINT INHIBITION, SUPPORTING UV1'S POTENTIAL AS A VALUABLE
COMBINATION THERAPY

Source text for Eikon:  ID:nGNEbcHtCR 
Further company coverage:  ULTI.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))